<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Palliative sedation
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Palliative sedation
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Palliative sedation
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nathan Cherny, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Thomas J Smith, MD, FACP, FASCO, FAAHPM
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Jane Givens, MD, MSCE
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jun 23, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H21551864">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Palliative sedation is a measure of last resort used at the end of life to relieve severe and refractory symptoms. It is performed by the administration of sedative medications in monitored settings and is aimed at inducing a state of decreased awareness or absent awareness (unconsciousness). The intent of palliative sedation is to relieve the burden of otherwise intolerable suffering for terminally ill patients in a manner that preserves the moral sensibilities of the patient, the medical professionals involved in their care, and concerned family and friends [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         This topic will review the indications and administration of palliative sedation in patients nearing the end of life as well as special applications of palliative sedation in other palliative care settings, such as in emergency situations, for respite, and for psychological distress. Other aspects of symptom care in the palliative setting are covered separately. (See
         <a class="medical medical_review" href="/z/d/html/2199.html" rel="external">
          "Overview of managing common non-pain symptoms in palliative care"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2814.html" rel="external">
          "Cancer pain management with opioids: Optimizing analgesia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2196.html" rel="external">
          "Approach to symptom assessment in palliative care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21551878">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Palliative sedation may be utilized in both adults and children [
         <a href="#rid2">
          2-6
         </a>
         ] with advanced incurable (ie, terminal) illness in order to alleviate severe symptoms that are refractory to other forms of treatment. It is most commonly utilized for the treatment of refractory pain, dyspnea, agitated delirium, and convulsions. However, there is much variability in the definition of “refractory” symptoms and thus in the prevalence of use of palliative sedation  (
         <a class="graphic graphic_table graphicRef88421" href="/z/d/graphic/88421.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Some emergency situations for which palliative sedation could be considered may include massive hemorrhage, asphyxiation, an overwhelming pain crisis, and severe terminal dyspnea [
         <a href="#rid8">
          8-10
         </a>
         ]. (See
         <a class="local">
          'Emergency sedation'
         </a>
         below.)
        </p>
        <p>
         Still, other than in emergency situations, intermittent or mild sedation should generally be attempted before deep and continuous sedation. For some patients, a state of "conscious sedation," in which the ability to respond to verbal stimuli is retained, may provide adequate relief without total loss of interactive function.
        </p>
        <p class="headingAnchor" id="H973825342">
         <span class="h2">
          Defining refractory symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         A symptom is considered "refractory" when it cannot adequately be controlled by therapies that do not seriously compromise consciousness and when it is associated with intolerable suffering on the part of the patient. The diagnostic criteria for "refractoriness" are based on the clinician’s determination that further invasive and noninvasive interventions meet any of the following [
         <a href="#rid1">
          1
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Incapable of providing adequate relief
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Associated with excessive and intolerable acute or chronic adverse effects
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unlikely to provide relief within a tolerable time frame
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H327805840">
         <span class="h1">
          CONCERNS OF STAFF, FAMILY, AND OTHERS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Witnessing or just considering palliative sedation can be profoundly distressing to family, other loved ones, and staff. This is particularly true if there is concern regarding the effects and ethics of palliative sedation, if there is lingering disagreement regarding the treatment plan among providers, and in situations where the process is protracted.
        </p>
        <p class="headingAnchor" id="H11453137">
         <span class="h2">
          Are we hastening death?
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple studies have attempted to measure the impact of palliative sedation on patient survival, and their overall conclusion is that survival is the same (or even better) when sedated patients are compared with non-sedated patients [
         <a href="#rid11">
          11-18
         </a>
         ]. These studies, while important, share methodological limitations that detract from the certainty of their conclusions: they are all cohort studies, most did not incorporate cohort matching for prognostic factors, and many did not detail the degree of sedation in the intervention arm.
        </p>
        <p class="headingAnchor" id="H769476216">
         <span class="h2">
          Other ethical concerns
         </span>
         <span class="headingEndMark">
          —
         </span>
         Some family members, loved ones, or staff may be concerned that palliative sedation is a form of euthanasia.
        </p>
        <p>
         The discussion of ethical issues with family or other loved ones and care team members should address the distinction from euthanasia. Palliative sedation is distinct from euthanasia in that euthanasia refers to the deliberate termination of the life of a patient by active intervention, usually at the request of the patient (voluntary active euthanasia [VAE]). Palliative sedation, by contrast, is utilized for refractory suffering and the intent of the intervention is to provide symptom relief, not expressly to end the life of the suffering patient [
         <a href="#rid19">
          19-27
         </a>
         ]; the intervention is proportionate to the prevailing symptom, its severity, and the prevailing goals of care; and, unlike euthanasia, death of the patient is not a criterion used to gauge the success of the treatment.
        </p>
        <p>
         Discussions with family members or other loved ones should emphasize that uncontrolled suffering at the end of life constitutes a critical situation and that the option of palliative sedation, after obtaining informed consent by the patient (or their surrogate) or by previously determined advance directives, constitutes a proportionate and effective response to suffering that is within accepted medical guidelines and supported by the principles of patient autonomy and self-determination [
         <a href="#rid28">
          28
         </a>
         ]. In this context, the decision to offer the use of sedation to relieve intolerable suffering to terminally ill patients presents no new ethical problem [
         <a href="#rid29">
          29,30
         </a>
         ] and is supported by legal precedent [
         <a href="#rid31">
          31-33
         </a>
         ]. (See
         <a class="local">
          'Obtaining consent'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2202.html" rel="external">
          "Ethical issues in palliative care", section on 'Palliative sedation'
         </a>
         .)
        </p>
        <p>
         Some assume that palliative sedation requires the concurrent discontinuation of nutrition and hydration [
         <a href="#rid34">
          34-37
         </a>
         ]. Therefore, they argue that while palliative sedation for the relief of uncontrolled symptoms may be justifiable, it almost certainly hastens death by allowing for starvation and dehydration. However, it is important to assert that the discontinuation of hydration and nutrition is
         <strong>
          not
         </strong>
         an essential element to the administration of sedation in the management of refractory symptoms [
         <a href="#rid38">
          38
         </a>
         ]. (See
         <a class="local">
          'The role of nutrition and hydration'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H769476784">
         <span class="h3">
          Ethically problematic practices
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians using palliative sedation need to be aware of the potential for harm from abusive, injudicious, or unskilled use of sedation. Potential harm is illustrated in the following examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation as a means of hastening death – This is the most common abuse of palliative sedation. It may occur by the deliberate use of deep sedation in patients who have no refractory symptoms, or in the deliberate use of doses that far exceed what is necessary to provide adequate comfort [
         <a href="#rid19">
          19-26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation applied inappropriately – Palliative sedation may be used for an inappropriate indication due to inadequate patient assessment that may have overlooked a potentially reversible cause of distress [
         <a href="#rid20">
          20,39
         </a>
         ]. For patients in whom palliative sedation is being considered, consultation with palliative care experts or a multidisciplinary team may help identify potential and available alternatives to palliative sedation [
         <a href="#rid20">
          20,40
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation given in response to the family’s (or others’) wishes and not in response to the patient themselves (or their advance directives) [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Sedation withheld when it is appropriate – This may occur when clinicians rule out or do not offer the option of palliative sedation in favor of other therapeutic options that do not provide adequate relief. This may occur when anxiety about having to deal with all of the difficult discussions about sedation and end-of-life care results in continued futile therapeutic trials of ineffective therapies or when there are reservations based on undue concerns about potentially hastening death.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H11453237">
         <span class="h2">
          Approach to the care team
         </span>
         <span class="headingEndMark">
          —
         </span>
         The care team should recognize the potential for staff distress [
         <a href="#rid42">
          42,43
         </a>
         ]. All participating staff members need to understand the rationale for sedation and goals of care. Whenever possible, this should be addressed at team meetings or case conferences, both before and after the event, to discuss the professional and emotional issues related to such decisions. Distress can be mitigated by fostering a culture of sensitivity to the emotional burdens involved in care, participating in the deliberative processes leading up to a treatment decision, sharing information, and engaging in multidisciplinary discussions that offer the group or individuals opportunities to express their feelings.
        </p>
        <p class="headingAnchor" id="H327805899">
         <span class="h2">
          Approach to the patient's family and friends
         </span>
         <span class="headingEndMark">
          —
         </span>
         Palliative sedation can be a welcomed method to assure patient comfort but can also be profoundly distressing to the patient’s family members and/or friends [
         <a href="#rid28">
          28
         </a>
         ]. A few principles are useful when considering the approach to a patient’s loved ones:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They should be allowed and encouraged to be with the patient. In many situations, an opportunity to say good-bye is of critical importance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They often need repeated reassurance that other methods have been sufficiently tried and/or carefully considered but were ineffective and that sedation is unlikely to shorten the patient’s life. The conversation should also emphasize the importance of comfort and our obligation to prevent or alleviate suffering.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         They should be kept informed about the patient’s wellbeing and what to expect.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The care team must provide supportive care to the members of the patient’s family and/or friends. This includes listening to their concerns, attention to grief and physical/psychological burdens, and awareness for any perceived feelings of guilt. In addition, they should be offered advice as to ways to be of help to the patient (eg, by being with, talking to, and touching the patient, providing mouth care, and managing the atmosphere of the patient’s care).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The care team should provide regular information updates to the family or other loved ones including information about the patient’s condition, degree of suffering, anticipated changes, or, when appropriate, notification that death is approaching and what can be expected in the dying process.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         After the death of the patient, the family or other loved ones should be offered the opportunity to meet with his or her care providers to give them the opportunity to ventilate grief and to discuss any outstanding concerns that they may harbor about the care delivered in the last days of life.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21551892">
         <span class="h1">
          PROCESS
         </span>
        </p>
        <p class="headingAnchor" id="H1550889671">
         <span class="h2">
          Advanced care planning
         </span>
         <span class="headingEndMark">
          —
         </span>
         Palliative sedation may be discussed as a component of a “goals of care” discussion when death is not imminent but a patient with advanced illness is at risk of intolerable suffering, and the clinician anticipates a potential need for it in the future. The discussion of this option should include review of the aims, benefits, and risks of palliative sedation, as well as the alternatives to its use (see
         <a class="medical medical_review" href="/z/d/html/95552.html" rel="external">
          "Discussing goals of care"
         </a>
         ). When the potential for catastrophic events such as bleeding or extreme distress is foreseen, contingency plans for the management of these events should be discussed, including the potential role of palliative sedation.
        </p>
        <p class="headingAnchor" id="H434480314">
         <span class="h2">
          Patient assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         However, most often the discussion about palliative sedation takes place because of a symptom crisis.
        </p>
        <p>
         Terminally ill patients suffering from severe distress should be evaluated urgently, preferably by a palliative care clinician. This evaluation is to determine whether reversible (or treatable) factors may be playing a role in the patient’s deterioration or severe distress (eg, acute bowel obstruction, elevated intracranial pressure, or a previously undiagnosed pulmonary infection). In addition, this allows for a re-evaluation of the patient’s prognosis, which is essential in order to allow for the discussion of appropriate therapy.
        </p>
        <p>
         In general, if palliative sedation is under consideration, review of the case by a multidisciplinary team (eg, involving a palliative care team or such specialists as psychiatrists or pain specialists) should be conducted in order to assure that all other reasonable treatments have been provided and that palliative sedation meets the patient’s goals [
         <a href="#rid44">
          44,45
         </a>
         ]. When local expertise is limited, telephone consultation with experts in palliative medicine is strongly encouraged.
        </p>
        <p class="headingAnchor" id="H21551899">
         <span class="h2">
          Obtaining consent
         </span>
         <span class="headingEndMark">
          —
         </span>
         When patients with advanced illness are at risk of intolerable suffering, clinicians should discuss the option of palliative sedation at a time before the patient is in a crisis situation. The discussion of this option should include review of the aims, benefits, and risks of palliative sedation, as well as the alternatives to its use.
        </p>
        <p>
         For patients experiencing severe or refractory distress but who are still conscious, alert, and communicative, a discussion on palliative sedation should be a part of a more comprehensive conversation that includes the following:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient’s general condition and the cause of the distress
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acknowledgement that prior treatments have not been successful
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current prognosis, including predictions about survival
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rationale, aims, and methods available for the use of palliative sedation, including the depth of planned sedation, patient monitoring, and, if appropriate, the possibility of planned weaning from sedation and even discontinuation
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alternative treatment options, the likelihood that they may relieve distress, and the expected survival associated with each
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anticipated effects of sedation, including degree of reduction in consciousness levels and the estimated effects on mental activities, communication, and oral intake
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Potential risks such as paradoxical agitation, delayed or inadequate relief, and the possibility of hastened death
        </p>
        <p>
        </p>
        <p>
         For patients who lack decisional capacity, the advance care plan of the patient should be followed. If there is no advance directive, the discussion regarding palliative sedation (including consent) must be obtained from a legally recognized proxy. When the patient is a child, consent of a parent or other guardian is required; however, care options might be discussed in an age-appropriate manner for older children to facilitate their agreement (or assent) [
         <a href="#rid6">
          6,46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6252.html" rel="external">
          "Pediatric palliative care"
         </a>
         .)
        </p>
        <p>
         For terminally ill patients who are actively dying and in severe distress, an opportunity to obtain consent by the patient or their health care proxy may not be present. In the absence of an advance directive or health care proxy, the provision of comfort measures (including, if necessary, the use of sedation) should be considered standard of practice and the default strategy for clinician treatment decisions.
        </p>
        <p>
         Regardless of whether the patient has decisional capacity or not, patients, their families and loved ones should be reassured that they will receive the best possible care during this time, irrespective of decisions to proceed with palliative sedation or an alternative treatment. In addition, patients should be informed that medical treatments and nursing care will be provided to ensure that the patient’s comfort is maintained and that the patient’s and family or other loved one’s wishes are respected.
        </p>
        <p class="headingAnchor" id="H21551906">
         <span class="h2">
          Sedative medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          Midazolam
         </a>
         is a short half-life benzodiazepine with a rapid onset of action and, administered parenterally, it is the most commonly used medication for palliative sedation [
         <a href="#rid18">
          18,47-49
         </a>
         ]. In one prospective study, 24 of 176 patients (14 percent) receiving palliative care at home underwent palliative sedation using a stepwise administration of midazolam [
         <a href="#rid50">
          50
         </a>
         ], which was administered predominantly due to agitated delirium. Based on the home care team and the individual patient’s relative's experience, the use of midazolam was felt to be effective at minimizing distress and most expressed satisfaction with the procedure.
        </p>
        <p>
         An alternative to benzodiazepine option is
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         , which has a slower onset of action (10 minutes) compared with
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         (two minutes).
        </p>
        <p>
         Alternative agents used in this context include
         <a class="drug drug_general" data-topicid="10147" href="/z/d/drug information/10147.html" rel="external">
          levomepromazine
         </a>
         [
         <a href="#rid51">
          51,52
         </a>
         ],
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         [
         <a href="#rid53">
          53,54
         </a>
         ],
         <a class="drug drug_general" data-topicid="9763" href="/z/d/drug information/9763.html" rel="external">
          phenobarbital
         </a>
         [
         <a href="#rid55">
          55,56
         </a>
         ], and
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         [
         <a href="#rid57">
          57-61
         </a>
         ]. These medications are reviewed in a table  (
         <a class="graphic graphic_table graphicRef88423" href="/z/d/graphic/88423.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H21551913">
         <span class="h2">
          Administration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sedation for the management of refractory symptoms is most commonly performed in an inpatient setting. However, substantial experience has been reported in home care settings [
         <a href="#rid62">
          62-65
         </a>
         ], which may be a preferred alternative for some patients.
        </p>
        <p>
         Administration of the selected medication initially requires dose titration to achieve adequate relief, followed by ongoing therapy to ensure maintenance of the effect. In general, the level of sedation should be the least necessary to provide adequate relief of suffering. Regular, "around the clock" administration can be maintained by continuous infusion or intermittent bolus.
        </p>
        <p>
         The route of administration can be intravenous, intramuscular, subcutaneous, or rectal; in some situations, drugs can also be administered via a stoma or gastrostomy. In all cases, provision for emergency bolus therapy to manage breakthrough symptoms is recommended.
        </p>
        <p>
         If mild sedation is ineffective, deeper levels of sedation should be performed. This is especially true in cases of refractory suffering when death is imminent and in the case of a catastrophic event (eg, massive hemorrhage or asphyxia). (See
         <a class="medical medical_review" href="/z/d/html/83242.html" rel="external">
          "Palliative care: Overview of cough, stridor, and hemoptysis in adults", section on 'Management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21551920">
         <span class="h2">
          Patient monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once adequate relief has been achieved, the parameters for patient monitoring and the role of further dose titration are determined by the clinical situation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient is imminently dying – We do not perform routine monitoring of vital signs (eg, pulse, blood pressure, and temperature) for patients nearing death. The only critical parameters for ongoing observation are those pertaining to comfort. Since downward titration of drug doses places the patient at risk for recurrent distress, it is not recommended in most instances. Respiratory rate is monitored primarily to ensure the absence of respiratory distress and tachypnea. A gradual
         <strong>
         </strong>
         deterioration of respiration is expected as patients near death and this alone should not constitute a reason to decrease sedation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patient is not imminently dying – Monitoring may be undertaken to preserve physiological stability for terminally ill patients who are not imminently dying. This may include repeat assessment of the level of sedation and routine physiological parameters such as heart rate, blood pressure, and oxygen saturation. If life-threatening obtundation with respiratory depression occurs, a lower treatment dose may be required. If patients become more unstable, the careful administration of a benzodiazepine antagonist (
         <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">
          flumazenil
         </a>
         ) may be appropriate. IV flumazenil 0.2 mg can be administered over one to two minutes and repeated up to every 15 minutes (maximum total dose 1 mg) until obtundation is reversed. Since its duration effect is short (0.7 to 1.3 hours), relapse may be treated in adults by using additional 0.2 mg doses until the desired effect is achieved or by a continuous flumazenil infusion (0.25 to 1 mg per hour) [
         <a href="#rid66">
          66
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Once sedation and symptom control is achieved, doses can be titrated down to reestablish lucidity if appropriate, if this was desired by the patient prior to sedation. This enables an opportunity to reevaluate the patient's condition and their preferences regarding sedation. It may also allow for patient to communicate with family or other loved ones. However, lucidity may not be restored, symptoms may reoccur, and death may intervene.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21551927">
         <span class="h2">
          The role of nutrition and hydration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Decisions regarding the administration of hydration and/or artificial nutrition therapy are independent of the decision about whether to administer palliative sedation. Although sedation is clearly beneficent in terms of providing relief of otherwise intolerable suffering, the beneficence of withdrawal of nutrition and hydration in the already sedated and comfortable patient is not self-evident, and indeed it may be perceived as harmful.
        </p>
        <p>
         Medically, there are few data to support the clinical benefit of hydration or artificial nutrition in the imminently dying, or to suggest that it prolongs life or contributes to comfort. Despite this, the withdrawal of potentially death-deferring treatments (such as hydration) among dying patients is, for some, controversial. Opinions and practices vary and reflect the heterogeneity of attitudes of involved clinicians, ethicists, patients, families, and local norms of good clinical and ethical practice. In cases where there are religious or culturally based reservations regarding the discontinuation of nutritional support, it should be maintained unless there is evidence of direct patient harm by the intervention. The topic of nutrition and hydration as part of end-of-life care is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14244.html" rel="external">
          "Stopping nutrition and hydration at the end of life"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1550889742">
         <span class="h2">
          Administration of previous medications
         </span>
         <span class="headingEndMark">
          —
         </span>
         Medications for symptom palliation used before sedation should be continued unless they are ineffective or have distressing side effects. Medications that are either inconsistent with or irrelevant to the goal of patient comfort can be discontinued. Special caution must be exercised regarding medications that may be associated with withdrawal responses, and in general such medication should not be discontinued [
         <a href="#rid67">
          67
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14241.html" rel="external">
          "Palliative care: The last hours and days of life", section on 'Eliminating non-essential medications'
         </a>
         .)
        </p>
        <p>
         In most cases, patients who were on pain medications (eg, opioids) prior to sedation should be continued on them unless adverse effects or signs of overdose (eg, respiratory suppression) are observed, in which case dose modifications may be necessary. If symptoms of an overdose are observed, opioid doses should be reduced but should not be rapidly withdrawn because of the risk of withdrawal.
        </p>
        <p class="headingAnchor" id="H616539533">
         <span class="h1">
          SPECIAL APPLICATIONS OF SEDATION IN PALLIATIVE CARE
         </span>
        </p>
        <p class="headingAnchor" id="H465738998">
         <span class="h2">
          Emergency sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Emergency sedation refers to the use of sedation to provide urgent relief of overwhelming symptoms in dying patients. Emergency situations may include massive hemorrhage, asphyxiation, severe terminal dyspnea, or overwhelming pain crisis [
         <a href="#rid8">
          8-10
         </a>
         ]. If a catastrophic situation is anticipated, advance care directives should be discussed with the patient, family members, other loved ones, and health care providers. (See
         <a class="local">
          'Obtaining consent'
         </a>
         above.)
        </p>
        <p>
         For patients who are at home and at risk of a catastrophic event, sedating medications should be prepared in advance and accompanied by a clear plan for emergency administration. In situations in which family members or other home carers feel that they would be unable to administer emergency medications, consideration should be given to inpatient care.
        </p>
        <p class="headingAnchor" id="H465739005">
         <span class="h2">
          Respite sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Respite sedation refers to the transient use of sedation to relieve severe symptoms (eg, malaise, pain, agitation, and nausea) that are not necessarily refractory, to provide adequate relief before continuing with further trial of nonsedating palliative approaches. After such respite, some patients will be sufficiently rested to consider further trials of symptomatic therapy [
         <a href="#rid55">
          55,56,68
         </a>
         ].
        </p>
        <p>
         Since the aim of respite sedation is to ultimately restore the patient to their pretreatment state of consciousness, precautions are required to ensure patient safety and to minimize risks. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Administration of the lowest effective dose of the sedative agent chosen that provides adequate comfort
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Monitoring routine physiological parameters
        </p>
        <p>
        </p>
        <p>
         If
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         is used,
         <a class="drug drug_general" data-topicid="8456" href="/z/d/drug information/8456.html" rel="external">
          flumazenil
         </a>
         should be readily available in case of inadvertent overdose. Despite these precautions, this approach is associated with significant risks (including the risk that level of consciousness may not be completely restored) that should be considered in the consent process. (See
         <a class="local">
          'Obtaining consent'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H465739012">
         <span class="h2">
          Use of sedation in the management of refractory existential or psychological distress
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sedation in the management of refractory psychological symptoms and existential distress is controversial and is different from the use of palliative sedation in other situations for several reasons [
         <a href="#rid69">
          69-72
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Due to the nature of the symptoms being addressed, it is much more difficult to establish that they are truly refractory.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The severity of distress of some symptoms may be very dynamic and idiosyncratic (ie, difficult to predict); in such cases, psychological adaptation and coping are common.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The standard treatment approaches to address severe psychological symptoms or existential distress are not intrinsically life-threatening, such as the use of psychotherapy, religious counseling, and spiritual support [
         <a href="#rid70">
          70
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unlike physical symptoms such as pain or dyspnea, the presence of these severe psychological symptoms or existential distress does not necessarily indicate a far-advanced state of physiological deterioration.
        </p>
        <p>
        </p>
        <p>
         The European Association for Palliative Care (EAPC) has provided a framework for addressing the use of palliative sedation in these circumstances [
         <a href="#rid73">
          73
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         This approach should be reserved for patients in advanced stages of a terminal illness.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The designation of such symptoms as refractory should only be made following a period of repeated assessment by clinicians skilled in psychological care who have established a relationship with the patient and their family or other loved ones along with trials of routine approaches for anxiety, depression, and existential distress.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Because of the complexity and frequently multifactorial nature of this situation, the evaluation should be made in the context of a multidisciplinary case conference, including representatives from psychiatry, chaplaincy, and ethics as well as those providing care at the bedside.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In the rare situations that this strategy is indeed appropriate and proportionate to the situation, it should be initiated on a respite basis for 6 to 24 hours with planned downward titration after a pre-agreed interval.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Only after repeated trials of respite sedation with intensive intermittent therapy have been performed should continuous sedation be considered.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H21552012">
         <span class="h1">
          GUIDELINES FROM MEDICAL GROUPS
         </span>
         <span class="headingEndMark">
          —
         </span>
         For palliative sedation to be used humanely and appropriately, appropriate attention to these processes is essential. While acknowledging that specific best practices have not been rigorously developed, procedural guidelines at the institutional level are necessary for clinicians to have a framework for decision-making and implementation. This promotes and protects the interests of patients, their families or other loved ones, and the health care providers administering care. Sound procedural guidelines such as checklists can reduce the risk of adverse outcomes in medicine [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
         Representative guidelines have been developed at a national, local, and institutional level [
         <a href="#rid49">
          49,73,76-90
         </a>
         ]. There are several inconsistencies throughout the positions taken by organizations on palliative sedation, most notably the timing of initiating palliative sedation, the level and pattern of sedation, whether or not existential distress is an indication, and the continuation versus discontinuation of life-sustaining therapies [
         <a href="#rid89">
          89,90
         </a>
         ]. Discrepancies in these areas are largely due to a number of ethical and clinical factors that make these decisions very difficult.
        </p>
        <p>
         However, several core factors are in agreement among most position statements on palliative sedation:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The patient must have a terminal illness where death is imminent (though the definition of imminent is variable).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The physical symptoms that the patient is experiencing are intractable and refractory to the most aggressive interventions, with no other options for treatment that would be effective within the estimated time left before expected death.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The intention of the intervention is symptom relief.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The plan of sedation and the risk-benefit profile should be made explicitly in an informed consent obtained from the patient or, if incapable, the surrogate, family, or other loved ones prior to initiation of palliative sedation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The decision to use palliative sedation must be discussed among an interdisciplinary team, ideally led by an experienced palliative care clinician.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Documentation of the informed consent and the provision of sedation must be thorough.
        </p>
        <p>
        </p>
        <p>
         The European Association for Palliative Care (EAPC) has developed a 10-item framework that addresses the key clinical issues to be considered when institutions are developing guidelines for palliative sedation in the management of refractory physical symptoms at the end of life. These are summarized in a table  (
         <a class="graphic graphic_table graphicRef88429" href="/z/d/graphic/88429.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1700585158">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/119531.html" rel="external">
          "Society guideline links: Palliative care"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H21552026">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Palliative sedation is the monitored use of sedating medications to induce a state of decreased awareness or complete unconsciousness in order to relieve the burden of otherwise intolerable suffering at the end of life. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Palliative sedation may be utilized in both adults and children with advanced incurable (ie, terminal) illness in order to alleviate severe symptoms that are refractory to other forms of treatment. The most common symptoms include pain, dyspnea, agitated delirium, and convulsions. (See
         <a class="local">
          'Indications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Although the data are limited, compared with patients at the end of life who did not receive palliative sedation, the use of palliative sedation does not appear to shorten survival in this setting. (See
         <a class="local">
          'Are we hastening death?'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients who are acutely suffering should be evaluated urgently, preferably by a clinician with experience and expertise in palliative care. (See
         <a class="local">
          'Advanced care planning'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Irrespective of the agent selected for palliative sedation, administration initially requires dose titration to achieve adequate relief, followed by ongoing therapy to ensure maintenance of effect. In general, the level of sedation should be the least necessary to provide adequate relief of suffering. (See
         <a class="local">
          'Administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients undergoing palliative sedation, monitoring should be tailored to their clinical status (see
         <a class="local">
          'Patient monitoring'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are actively dying, we do not perform routine monitoring of vital signs (eg, pulse, blood pressure, and temperature). The only critical parameters for ongoing observation are those pertaining to comfort.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         For patients who are not actively dying, monitoring is reasonable, including repeat assessment of the level of sedation and routine physiological parameters such as heart rate, blood pressure, and oxygen saturation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The decision about artificial hydration and/or nutrition therapy is made independently of the decision about palliative sedation itself. (See
         <a class="local">
          'The role of nutrition and hydration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Medications for symptom palliation used before initiating palliative sedation should be continued, unless they are ineffective or have distressing side effects. Medications that are either inconsistent with, or irrelevant to, the goal of patient comfort can generally be discontinued. (See
         <a class="local">
          'Administration of previous medications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Loved ones often need repeated reassurance that other methods have been sufficiently trialed but were ineffective in alleviating suffering and that palliative sedation is unlikely to shorten the patient’s life. (See
         <a class="local">
          'Approach to the patient's family and friends'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The care team should recognize the potential for staff distress. All participating staff members need to understand the rationale for sedation and goals of care. Whenever possible this should be addressed at team meetings or case conferences, both before and after the event, to discuss the professional and emotional issues related to such decisions. (See
         <a class="local">
          'Approach to the care team'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Special applications of palliative sedation include (see
         <a class="local">
          'Special applications of sedation in palliative care'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of sedation to provide urgent relief of overwhelming symptoms in dying patients (emergency palliative sedation)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Transient use of sedation to relieve severe symptoms that are not necessarily refractory (respite palliative sedation)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The use of sedation to manage refractory psychological symptoms and existential distress is controversial but may be appropriate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Palliative sedation is not synonymous with voluntary active euthanasia (VAE). VAE refers to the deliberate termination of the life of a patient by active intervention, usually at the request of the patient. Palliative sedation is not meant to be a means of hastening the patient’s death. (See
         <a class="medical medical_review" href="/z/d/html/95251.html" rel="external">
          "Medical aid in dying: Ethical and legal issues"
         </a>
         and
         <a class="local">
          'Other ethical concerns'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We encourage the development of guidelines on a local level to establish criteria for the use of palliative sedation. We agree with the European Association for Palliative Care (EAPC)’s 10-item framework that addresses the key clinical issues in palliative sedation for the management of refractory physical symptoms at the end of life. (See
         <a class="local">
          'Guidelines from medical groups'
         </a>
         above.)
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Cherny NI, Portenoy RK. Sedation in the management of refractory symptoms: guidelines for evaluation and treatment. J Palliat Care 1994; 10:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anghelescu DL, Hamilton H, Faughnan LG, et al. Pediatric palliative sedation therapy with propofol: recommendations based on experience in children with terminal cancer. J Palliat Med 2012; 15:1082.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pousset G, Bilsen J, Cohen J, et al. Continuous deep sedation at the end of life of children in Flanders, Belgium. J Pain Symptom Manage 2011; 41:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhlen M, Schneider K, Richter U, et al. Palliative sedation in 2 children with terminal cancer - an effective treatment of last resort in a home care setting. Klin Padiatr 2011; 223:374.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kiman R, Wuiloud AC, Requena ML. End of life care sedation for children. Curr Opin Support Palliat Care 2011; 5:285.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Postovsky S, Moaed B, Krivoy E, et al. Practice of palliative sedation in children with brain tumors and sarcomas at the end of life. Pediatr Hematol Oncol 2007; 24:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roy DJ. Need they sleep before they die? J Palliat Care 1990; 6:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bishop MF, Stephens L, Goodrich M, Byock I. Medication kits for managing symptomatic emergencies in the home: a survey of common hospice practice. J Palliat Med 2009; 12:37.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Falk S, Fallon M. ABC of palliative care. Emergencies. BMJ 1997; 315:1525.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nauck F, Alt-Epping B. Crises in palliative care--a comprehensive approach. Lancet Oncol 2008; 9:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maltoni M, Scarpi E, Rosati M, et al. Palliative sedation in end-of-life care and survival: a systematic review. J Clin Oncol 2012; 30:1378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beller EM, van Driel ML, McGregor L, et al. Palliative pharmacological sedation for terminally ill adults. Cochrane Database Syst Rev 2015; 1:CD010206.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Daly BJ, Thomas D, Dyer MA. Procedures used in withdrawal of mechanical ventilation. Am J Crit Care 1996; 5:331.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell ML, Bizek KS, Thill M. Patient responses during rapid terminal weaning from mechanical ventilation: a prospective study. Crit Care Med 1999; 27:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson WC, Smedira NG, Fink C, et al. Ordering and administration of sedatives and analgesics during the withholding and withdrawal of life support from critically ill patients. JAMA 1992; 267:949.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Maeda I, Morita T, Yamaguchi T, et al. Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study. Lancet Oncol 2016; 17:115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rietjens JA, van Zuylen L, van Veluw H, et al. Palliative sedation in a specialized unit for acute palliative care in a cancer hospital: comparing patients dying with and without palliative sedation. J Pain Symptom Manage 2008; 36:228.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schur S, Weixler D, Gabl C, et al. Sedation at the end of life - a nation-wide study in palliative care units in Austria. BMC Palliat Care 2016; 15:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levy MH, Cohen SD. Sedation for the relief of refractory symptoms in the imminently dying: a fine intentional line. Semin Oncol 2005; 32:237.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hasselaar JG, Reuzel RP, van den Muijsenbergh ME, et al. Dealing with delicate issues in continuous deep sedation. Varying practices among Dutch medical specialists, general practitioners, and nursing home physicians. Arch Intern Med 2008; 168:537.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhse H, Singer P, Baume P, et al. End-of-life decisions in Australian medical practice. Med J Aust 1997; 166:191.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro RS, Derse AR, Gottlieb M, et al. Willingness to perform euthanasia. A survey of physician attitudes. Arch Intern Med 1994; 154:575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Willems DL, Daniels ER, van der Wal G, et al. Attitudes and practices concerning the end of life: a comparison between physicians from the United States and from The Netherlands. Arch Intern Med 2000; 160:63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meier DE, Emmons CA, Wallenstein S, et al. A national survey of physician-assisted suicide and euthanasia in the United States. N Engl J Med 1998; 338:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas CD, Kerridge IH, Rainbird KJ, et al. The intention to hasten death: a survey of attitudes and practices of surgeons in Australia. Med J Aust 2001; 175:511.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rietjens JA, van der Heide A, Vrakking AM, et al. Physician reports of terminal sedation without hydration or nutrition for patients nearing death in the Netherlands. Ann Intern Med 2004; 141:178.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Materstvedt LJ. Distinction between euthanasia and palliative sedation is clear-cut. J Med Ethics 2020; 46:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tursunov O, Cherny NI, Ganz FD. Experiences of Family Members of Dying Patients Receiving Palliative Sedation. Oncol Nurs Forum 2016; 43:E226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miller FG, Fins JJ, Bacchetta MD. Clinical pragmatism: John Dewey and clinical ethics. J Contemp Health Law Policy 1996; 13:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fins JJ, Bacchetta MD, Miller FG. Clinical pragmatism: a method of moral problem solving. Kennedy Inst Ethics J 1997; 7:129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gevers S. Terminal sedation: a legal approach. Eur J Health Law 2003; 10:359.
          </a>
         </li>
         <li class="breakAll">
          Easing the Passing, Devlin P (Ed), Bodley Head, London 1985.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burt RA. The Supreme Court speaks--not assisted suicide but a constitutional right to palliative care. N Engl J Med 1997; 337:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig GM. On withholding artificial hydration and nutrition from terminally ill sedated patients. The debate continues. J Med Ethics 1996; 22:147.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig GM. On withholding nutrition and hydration in the terminally ill: has palliative medicine gone too far? J Med Ethics 1994; 20:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Craig G. Is sedation without hydration or nourishment in terminal care lawful? Med Leg J 1994; 62:198.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orentlicher D. The Supreme Court and physician-assisted suicide--rejecting assisted suicide but embracing euthanasia. N Engl J Med 1997; 337:1236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hahn MP. Review of palliative sedation and its distinction from euthanasia and lethal injection. J Pain Palliat Care Pharmacother 2012; 26:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fainsinger RL, De Moissac D, Mancini I, Oneschuk D. Sedation for delirium and other symptoms in terminally ill patients in Edmonton. J Palliat Care 2000; 16:5.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray SA, Boyd K, Byock I. Continuous deep sedation in patients nearing death. BMJ 2008; 336:781.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Higgins PC, Altilio T. Palliative sedation: an essential place for clinical excellence. J Soc Work End Life Palliat Care 2007; 3:3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ziegler S, Merker H, Schmid M, Puhan MA. The impact of the inpatient practice of continuous deep sedation until death on healthcare professionals' emotional well-being: a systematic review. BMC Palliat Care 2017; 16:30.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leboul D, Aubry R, Peter JM, et al. Palliative sedation challenging the professional competency of health care providers and staff: a qualitative focus group and personal written narrative study. BMC Palliat Care 2017; 16:25.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldman HA, McKinlay JB, Potter DA, et al. Nonmedical influences on medical decision making: an experimental technique using videotapes, factorial design, and survey sampling. Health Serv Res 1997; 32:343.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christakis NA, Asch DA. Biases in how physicians choose to withdraw life support. Lancet 1993; 342:642.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fraser J, Harris N, Berringer AJ, et al. Advanced care planning in children with life-limiting conditions - the Wishes Document. Arch Dis Child 2010; 95:79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lux MR, Protus BM, Kimbrel J, Grauer P. A Survey of Hospice and Palliative Care Physicians Regarding Palliative Sedation Practices. Am J Hosp Palliat Care 2017; 34:217.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vivat B, Bemand-Qureshi L, Harrington J, et al. Palliative care specialists in hospice and hospital/community teams predominantly use low doses of sedative medication at the end of life for patient comfort rather than sedation: Findings from focus groups and patient records for I-CAN-CARE. Palliat Med 2019; 33:578.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Imai K, Morita T, Akechi T, et al. The Principles of Revised Clinical Guidelines about Palliative Sedation Therapy of the Japanese Society for Palliative Medicine. J Palliat Med 2020; 23:1184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercadante S, Porzio G, Valle A, et al. Palliative sedation in patients with advanced cancer followed at home: a prospective study. J Pain Symptom Manage 2014; 47:860.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliver DJ. The use of methotrimeprazine in terminal care. Br J Clin Pract 1985; 39:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dietz I, Schmitz A, Lampey I, Schulz C. Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review. BMC Palliat Care 2013; 12:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIver B, Walsh D, Nelson K. The use of chlorpromazine for symptom control in dying cancer patients. J Pain Symptom Manage 1994; 9:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LeGrand SB. Dyspnea: the continuing challenge of palliative management. Curr Opin Oncol 2002; 14:394.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Greene WR, Davis WH. Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer. South Med J 1991; 84:332.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Truog RD, Berde CB, Mitchell C, Grier HE. Barbiturates in the care of the terminally ill. N Engl J Med 1992; 327:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Collins P. Prolonged sedation with midazolam or propofol. Crit Care Med 1997; 25:556.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tobias JD. Propofol sedation for terminal care in a pediatric patient. Clin Pediatr (Phila) 1997; 36:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krakauer EL, Penson RT, Truog RD, et al. Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect. Oncologist 2000; 5:53.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercadante S, De Conno F, Ripamonti C. Propofol in terminal care. J Pain Symptom Manage 1995; 10:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moyle J. The use of propofol in palliative medicine. J Pain Symptom Manage 1995; 10:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercadante S, Porzio G, Valle A, et al. Palliative sedation in advanced cancer patients followed at home: a retrospective analysis. J Pain Symptom Manage 2012; 43:1126.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Setla J, Pasniciuc SV. Home Palliative Sedation Using Phenobarbital Suppositories: Time to Death, Patient Characteristics, and Administration Protocol. Am J Hosp Palliat Care 2019; 36:871.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caraceni A, Speranza R, Spoldi E, et al. Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study. J Pain Symptom Manage 2018; 56:33.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mercadante S, Masedu F, Mercadante A, et al. Attitudes of palliative home care physicians towards palliative sedation at home in Italy. Support Care Cancer 2017; 25:1615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zaporowska-Stachowiak I, Szymański K, Oduah MT, et al. Midazolam: Safety of use in palliative care: A systematic critical review. Biomed Pharmacother 2019; 114:108838.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laroche JP. Subcutaneous dexmedetomidine for baclofen withdrawal during palliative sedation. BMJ Support Palliat Care 2020; 10:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morita T, Inoue S, Chihara S. Sedation for symptom control in Japan: the importance of intermittent use and communication with family members. J Pain Symptom Manage 1996; 12:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rousseau P. Existential distress and palliative sedation. Anesth Analg 2005; 101:611.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taylor BR, McCann RM. Controlled sedation for physical and existential suffering? J Palliat Med 2005; 8:144.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ciancio AL, Mirza RM, Ciancio AA, Klinger CA. The Use of Palliative Sedation to Treat Existential Suffering: A Scoping Review on Practices, Ethical Considerations, and Guidelines. J Palliat Care 2020; 35:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Voeuk A, Nekolaichuk C, Fainsinger R, Huot A. Continuous Palliative Sedation for Existential Distress? A Survey of Canadian Palliative Care Physicians' Views. J Palliat Care 2017; 32:26.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cherny NI, Radbruch L, Board of the European Association for Palliative Care. European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care. Palliat Med 2009; 23:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haynes AB, Weiser TG, Berry WR, et al. A surgical safety checklist to reduce morbidity and mortality in a global population. N Engl J Med 2009; 360:491.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hoffman GM, Nowakowski R, Troshynski TJ, et al. Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model. Pediatrics 2002; 109:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean MM, Cellarius V, Henry B, et al. Framework for continuous palliative sedation therapy in Canada. J Palliat Med 2012; 15:870.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghafoor VL, Silus LS. Developing policy, standard orders, and quality-assurance monitoring for palliative sedation therapy. Am J Health Syst Pharm 2011; 68:523.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Verkerk M, van Wijlick E, Legemaate J, de Graeff A. A national guideline for palliative sedation in the Netherlands. J Pain Symptom Manage 2007; 34:666.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morita T, Bito S, Kurihara Y, Uchitomi Y. Development of a clinical guideline for palliative sedation therapy using the Delphi method. J Palliat Med 2005; 8:716.
          </a>
         </li>
         <li class="breakAll">
          Royal Dutch Medical Association Committee on National Guideline for Palliative Sedation. Available at http://www.scribd.com/doc/100581822/KNMG-Guideline-for-Palliative-Sedation-2009-2 (Accessed on March 16, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kirk TW, Mahon MM, Palliative Sedation Task Force of the National Hospice and Palliative Care Organization Ethics Committee. National Hospice and Palliative Care Organization (NHPCO) position statement and commentary on the use of palliative sedation in imminently dying terminally ill patients. J Pain Symptom Manage 2010; 39:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           National Ethics Committee, Veterans Health Administration. The ethics of palliative sedation as a therapy of last resort. Am J Hosp Palliat Care 2006; 23:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Braun TC, Hagen NA, Clark T. Development of a clinical practice guideline for palliative sedation. J Palliat Med 2003; 6:345.
          </a>
         </li>
         <li class="breakAll">
          Hospice and Palliative Care Federation of Massachusetts. Palliative Sedation Protocol: A Report of the Standards and Best Practices Committee, Hospice and Palliative Care Federation of Massachusetts 2004, Norwood, MA.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quill TE, Byock IR. Responding to intractable terminal suffering: the role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine. Ann Intern Med 2000; 132:408.
          </a>
         </li>
         <li class="breakAll">
          HPNA Position Statement: Palliative sedation at end of life; 2003 Hospice and Palliative Nurses Association Web site: http://hpna.advancingexpertcare.org/wp-content/uploads/2015/08/Palliative-Sedation.pdf (Accessed on November 05, 2015).
         </li>
         <li class="breakAll">
          American Academy of Hospice and Palliative Medicine. Statement on palliative sedation; 2013. http://aahpm.org/positions/palliative-sedation (Accessed on November 05, 2015).
         </li>
         <li class="breakAll">
          American Medical Association. Opinnion 2.201-sedation to unconsciousness in end of life care; 2008. http://www.ama-assn.org/ama/pub/physician-resources/medical-ethics/code-medical-ethics/opinion2201.page (Accessed on November 05, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gurschick L, Mayer DK, Hanson LC. Palliative Sedation: An Analysis of International Guidelines and Position Statements. Am J Hosp Palliat Care 2015; 32:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abarshi E, Rietjens J, Robijn L, et al. International variations in clinical practice guidelines for palliative sedation: a systematic review. BMJ Support Palliat Care 2017; 7:223.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 83710 Version 29.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8089815" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sedation in the management of refractory symptoms: guidelines for evaluation and treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22731512" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Pediatric palliative sedation therapy with propofol: recommendations based on experience in children with terminal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21145698" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Continuous deep sedation at the end of life of children in Flanders, Belgium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22052636" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Palliative sedation in 2 children with terminal cancer - an effective treatment of last resort in a home care setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21734584" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : End of life care sedation for children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17710658" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Practice of palliative sedation in children with brain tumors and sarcomas at the end of life.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1700096" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Need they sleep before they die?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19284261" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Medication kits for managing symptomatic emergencies in the home: a survey of common hospice practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9420498" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : ABC of palliative care. Emergencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19012857" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Crises in palliative care--a comprehensive approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22412129" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Palliative sedation in end-of-life care and survival: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25879099" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Palliative pharmacological sedation for terminally ill adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8870856" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Procedures used in withdrawal of mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9934896" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Patient responses during rapid terminal weaning from mechanical ventilation: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1370853" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Ordering and administration of sedatives and analgesics during the withholding and withdrawal of life support from critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26610854" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Effect of continuous deep sedation on survival in patients with advanced cancer (J-Proval): a propensity score-weighted analysis of a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18411017" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Palliative sedation in a specialized unit for acute palliative care in a cancer hospital: comparing patients dying with and without palliative sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27180238" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sedation at the end of life - a nation-wide study in palliative care units in Austria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15815971" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Sedation for the relief of refractory symptoms in the imminently dying: a fine intentional line.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18332301" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Dealing with delicate issues in continuous deep sedation. Varying practices among Dutch medical specialists, general practitioners, and nursing home physicians.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9066548" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : End-of-life decisions in Australian medical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8122951" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Willingness to perform euthanasia. A survey of physician attitudes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10632306" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Attitudes and practices concerning the end of life: a comparison between physicians from the United States and from The Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9554861" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : A national survey of physician-assisted suicide and euthanasia in the United States.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11795535" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The intention to hasten death: a survey of attitudes and practices of surgeons in Australia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15289214" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Physician reports of terminal sedation without hydration or nutrition for patients nearing death in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31217231" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Distinction between euthanasia and palliative sedation is clear-cut.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27768142" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Experiences of Family Members of Dying Patients Receiving Palliative Sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9068236" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical pragmatism: John Dewey and clinical ethics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11654986" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical pragmatism: a method of moral problem solving.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15176131" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Terminal sedation: a legal approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15176131" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Terminal sedation: a legal approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9337388" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The Supreme Court speaks--not assisted suicide but a constitutional right to palliative care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8798936" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : On withholding artificial hydration and nutrition from terminally ill sedated patients. The debate continues.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7527863" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : On withholding nutrition and hydration in the terminally ill: has palliative medicine gone too far?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11654339" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Is sedation without hydration or nourishment in terminal care lawful?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9340517" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : The Supreme Court and physician-assisted suicide--rejecting assisted suicide but embracing euthanasia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22448939" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Review of palliative sedation and its distinction from euthanasia and lethal injection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10887726" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sedation for delirium and other symptoms in terminally ill patients in Edmonton.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344246" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Continuous deep sedation in patients nearing death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18928079" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Palliative sedation: an essential place for clinical excellence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28482856" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : The impact of the inpatient practice of continuous deep sedation until death on healthcare professionals' emotional well-being: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28399846" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Palliative sedation challenging the professional competency of health care providers and staff: a qualitative focus group and personal written narrative study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9240285" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Nonmedical influences on medical decision making: an experimental technique using videotapes, factorial design, and survey sampling.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8103146" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Biases in how physicians choose to withdraw life support.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20172892" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Advanced care planning in children with life-limiting conditions - the Wishes Document.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26543063" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : A Survey of Hospice and Palliative Care Physicians Regarding Palliative Sedation Practices.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30747052" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Palliative care specialists in hospice and hospital/community teams predominantly use low doses of sedative medication at the end of life for patient comfort rather than sedation: Findings from focus groups and patient records for I-CAN-CARE.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32283043" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : The Principles of Revised Clinical Guidelines about Palliative Sedation Therapy of the Japanese Society for Palliative Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24099896" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Palliative sedation in patients with advanced cancer followed at home: a prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4063129" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : The use of methotrimeprazine in terminal care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23331515" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Evidence for the use of Levomepromazine for symptom control in the palliative care setting: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7963786" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : The use of chlorpromazine for symptom control in dying cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12130922" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Dyspnea: the continuing challenge of palliative management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1705723" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Titrated intravenous barbiturates in the control of symptoms in patients with terminal cancer.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1279424" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Barbiturates in the care of the terminally ill.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9118679" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Prolonged sedation with midazolam or propofol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9152556" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Propofol sedation for terminal care in a pediatric patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10706650" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8594125" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Propofol in terminal care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8594126" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : The use of propofol in palliative medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22651952" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Palliative sedation in advanced cancer patients followed at home: a retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30947512" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Home Palliative Sedation Using Phenobarbital Suppositories: Time to Death, Patient Characteristics, and Administration Protocol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29548893" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Palliative Sedation in Terminal Cancer Patients Admitted to Hospice or Home Care Programs: Does the Setting Matter? Results From a National Multicenter Observational Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28097432" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Attitudes of palliative home care physicians towards palliative sedation at home in Italy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30981104" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Midazolam: Safety of use in palliative care: A systematic critical review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30636205" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Subcutaneous dexmedetomidine for baclofen withdrawal during palliative sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8718914" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Sedation for symptom control in Japan: the importance of intermittent use and communication with family members.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16037198" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Existential distress and palliative sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15662185" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Controlled sedation for physical and existential suffering?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30757945" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : The Use of Palliative Sedation to Treat Existential Suffering: A Scoping Review on Practices, Ethical Considerations, and Guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28662627" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Continuous Palliative Sedation for Existential Distress? A Survey of Canadian Palliative Care Physicians' Views.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19858355" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : European Association for Palliative Care (EAPC) recommended framework for the use of sedation in palliative care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19144931" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : A surgical safety checklist to reduce morbidity and mortality in a global population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11826201" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Risk reduction in pediatric procedural sedation by application of an American Academy of Pediatrics/American Society of Anesthesiologists process model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22747192" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Framework for continuous palliative sedation therapy in Canada.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21378301" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Developing policy, standard orders, and quality-assurance monitoring for palliative sedation therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17618078" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : A national guideline for palliative sedation in the Netherlands.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16128645" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Development of a clinical guideline for palliative sedation therapy using the Delphi method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16128645" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Development of a clinical guideline for palliative sedation therapy using the Delphi method.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20471551" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : National Hospice and Palliative Care Organization (NHPCO) position statement and commentary on the use of palliative sedation in imminently dying terminally ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17211004" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : The ethics of palliative sedation as a therapy of last resort.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14509479" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Development of a clinical practice guideline for palliative sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14509479" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Development of a clinical practice guideline for palliative sedation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10691593" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Responding to intractable terminal suffering: the role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10691593" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Responding to intractable terminal suffering: the role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10691593" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Responding to intractable terminal suffering: the role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10691593" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Responding to intractable terminal suffering: the role of terminal sedation and voluntary refusal of food and fluids. ACP-ASIM End-of-Life Care Consensus Panel. American College of Physicians-American Society of Internal Medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24807825" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Palliative Sedation: An Analysis of International Guidelines and Position Statements.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28432090" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : International variations in clinical practice guidelines for palliative sedation: a systematic review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
